MICHAEL J. ANDERSON, M.D.; CAROL L. PEEBLES, M.S.; ROBERT McMILLAN, M.D.; JOHN G. CURD, M.D.
A positive test for antinuclear antibodies in a patient with chronic immune thrombocytopenic purpura often presents diagnostic and therapeutic problems. Immune thrombocytopenia is the earliest clinical manifestation in a small percentage (3% to 16%) of patients who subsequently develop systemic lupus erythematosus (1, 2). Early recognition of those patients with immune thrombocytopenia who will ultimately develop more serious manifestations of systemic lupus erythematosus would allow better management of their disease.
The fluorescent antinuclear antibody assay, although positive in patients with systemic lupus erythematosus, is not specific (3). The presence of autoantibodies to certain defined nuclear antigens is commonly associated with
ANDERSON MJ, PEEBLES CL, McMILLAN R, CURD JG. Fluorescent Antinuclear Antibodies and Anti-SS-A/Ro in Patients with Immune Thrombocytopenia Subsequently Developing Systemic Lupus Erythematosus. Ann Intern Med. ;103:548–550. doi: 10.7326/0003-4819-103-4-548
Download citation file:
Published: Ann Intern Med. 1985;103(4):548-550.
Lupus Erythematosus, Rheumatology.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use